Table 5.
Mean data of NSCLC diagnosis and decision parameters for each of the three randomly sampled patient groups at five examinations.
| CYFRA21-1 (μg/mL) |
CEA (μg/L) |
CA-125 (KU/L) |
NSE (μg/mL) |
CA242 (KU/L) |
PSA (μg/mL) |
HGH (μg/mL) |
Free-PSA (μg/mL) |
FERRITIN (KU/L) |
|---|---|---|---|---|---|---|---|---|
| 36.71 | 3.29 | 157.64 | 21 | 31 | 0.81 | 0.51 | 1.88 | 154.2 |
| 33.58 | 4.12 | 189.55 | 16 | 24 | 1.01 | 0.82 | 1.45 | 189.6 |
| 40.23 | 3.15 | 156.31 | 27 | 32 | 0.95 | 0.77 | 1.78 | 175.8 |
| 31.84 | 3.92 | 179.32 | 22 | 28 | 1.45 | 0.48 | 0.81 | 193.7 |
| 34.53 | 3.44 | 198.09 | 19 | 31 | 0.98 | 0.89 | 0.57 | 173.8 |
| 1.20 | 75.48 | 576.12 | 33 | 9 | 1.22 | 11.25 | 21.88 | 935.7 |
| 1.15 | 82.79 | 498.32 | 37 | 5 | 1.48 | 22.82 | 28.74 | 854.1 |
| 0.91 | 79.32 | 524.89 | 22 | 6 | 1.88 | 19.85 | 24.32 | 718.2 |
| 1.01 | 89.11 | 489.36 | 24 | 7 | 0.99 | 23.58 | 26.81 | 921.5 |
| 1.03 | 84.12 | 518.88 | 27 | 4 | 1.57 | 18.78 | 37.58 | 814.6 |
| 1.22 | 6.77 | 116.32 | 31 | 21 | 7.22 | 6.51 | 0.12 | 258.9 |
| 1.41 | 8.24 | 97.54 | 36 | 26 | 7.52 | 5.32 | 0.55 | 322.7 |
| 1.32 | 16.78 | 104.58 | 35 | 29 | 7.14 | 4.87 | 0.17 | 278.9 |
| 1.20 | 22.12 | 99.28 | 28 | 24 | 8.56 | 5.99 | 0.45 | 341.8 |
| 1.19 | 17.95 | 89.65 | 21 | 22 | 8.47 | 6.02 | 0.67 | 304.8 |